IRVINGTON, N.Y., Aug. 4, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release second quarter 2014 financial results on Wednesday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Chief Financial Officer, Robert Cook, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
Conference Call Details: | |
Date: | Wednesday, August 13, 2014 |
Time: | 4:30 p.m. Eastern Time |
Toll Free: | 800-274-0251 |
International: | 719-325-2284 |
Passcode: | 2866769 |
Webcast: | http://melasciences.com/investors/home |
Replays, Available through August 29: | |
Toll Free: | 877-870-5176 |
International: | 858-384-5517 |
Replay PIN: | 2866769 |
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature.